moderators: david cort, md alex denes, md panelists: stephen swisher, md, phd edward lin, md

34
Moderators: David Cort, MD Alex Denes, MD Panelists: Stephen Swisher, MD, PhD Edward Lin, MD

Upload: isabel-perry

Post on 30-Dec-2015

217 views

Category:

Documents


1 download

TRANSCRIPT

Moderators:David Cort, MDAlex Denes, MD

Panelists:Stephen Swisher, MD, PhD

Edward Lin, MD

Tumor staging

T1- confined to mucosa/submucosa

T2- extends to muscularis propria

T3- extends into surrounding tissue

T4 - involves major vessels, pleura, pericardium

Nodal staging

N0 - no nodes involved

N1 - local nodes involved

N2 - distant nodes involved

Esophagectomy

Combined modality Pre-operative chemo-radiation >>> esophagectomy Esophagectomy >>>> Post-operative chemo-radiation

Non surgical Definitive chemoradiation

Surgical margins Pathology margins

R0 No tumor No tumor

R1 No tumor Microscopic tumor present

R2 Tumor present Macroscopic tumor present

What are the usual sites of recurrence Local distant

Benefits Palliative chemo ± radiation

▪ survival benefit▪ Quality of life

Treatment of recurrence in lymph node outside the initial field of initial radiotherapy

How- Physical Exam- what signs to look for CT chest/abdomen- what findings to look for EGD – what symptoms should prompt it Serum CEA levels- ? In which patients EUS - ? role

How often Suggested protocols for follow up

A 52 year old accountant with known history of Barrett’s esophagus and symptomatic reflux

surveillance endoscopy. 5 cm segment of Barrett’s esophagus proximal to the GE

junction. ▪ Biopsy - Multiple foci of HGD

1.5 cm sessile polypoid lesion at the GEJ▪ Biopsy- Invasive adenocarcinoma.

T1- confined to the mucosa and submucosa and sparing the muscularis propria.

N0 – no enlarged lymph nodes

PET/CT: No nodal or distant metastases

He undergoes esophagectomy without complications (R0 resection)

Surg path: T1, N0, (M0) moderately differentiated adenocarcinoma, No lympho-vascular infiltration multiple foci of Barrett’s all margins clear of tumor

1. CT chest and abdomen every 3 months2. CT chest and abdomen every 6 months3. CXR every 3 months4. EGD every 3 months5. All of the above6. None of the above

AQ1. Appropriate post treatment follow-up of this patient would involve

What are the chances of tumor recurrence

What are the usual sites of recurrence Local

▪ Treatment options▪ Benefits

Distant▪ Treatment options▪ Benefits

Suggested follow up after treatment

T1N0 GEJ

The cure rate 80-90%.

If EMR or radiation cure rate 60-70% (then regular EGD is indicated).

Q 6 months for the first 2 years, then annual

physical exams with routine blood work.

Imaging only when clinically indicated.

Repeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasia

No CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negative

Repeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasia

No CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negative

A 65 year old house-wife with history of GERD presents with progressive dysphagia

EGD: An irregular, non obstructing, ulcerated mass in the

distal esophagus. Biopsy: Moderately differentiated adenocarcinoma

EUS: T3 tumor (infiltrating muscularis propria) No enlarged lymph nodes

PET/CT: intense FDG uptake in the distal esophageal mass no lymph node or distant metastases

Planned treatment: Pre-operative chemoradiation followed by surgery

Patient recieves combined modality therapy with radiation and chemotherapy Follow up EGD:

▪ no residual mass and biopsy shows only radiation effect.

Patient is now reluctant about proceeding with esophagectomy

1. Convince the patient to proceed with surgery as originally planned

2. Give additional chemo-radiation to full dose

3. Can wait and see how the patient performs

4. None of the above

RTOG-Hersovic: Chemo-RT > RT: 5-year 32%, vs 12% 20% vs 0% 10 year survival. LR > 45%

Intergroup 0123: 50.4 Gy > 64.8 Gy

Phase III: Modern RT = S

CMT vs S: OR 0.53-0.86. Three Meta-analysis (Ref 1-3). (Many small studies isolated positive study mostly with 5FU/Cisplatin/50.4 cGy.

Urschel Am J Surgery 2003:6:553. 1. Surgery 2005; 137:1727 2. Gut 2004;7:925 3. Walsh et la. NEJM.1997 Kelsen DP NEJM 1998; Yu ASCO 2006 Abst 4012

Chances of tumor recurrence Sites of tumor recurrence

Local distant

Treatment options Salvage esophagectomy

Suggested follow up

CT or CT/PET and endoscopy with biopsies q 3 months x2 then 6month x 3 then yearly (RTOG 0246) Early follow/up similar survival to

trimodality

Esophagectomy R0 resection Path:

▪ No residual carcinoma in the esophagus ▪ 12 lymph nodes are clear

What are the chances of tumor recurrence

What are the usual sites of recurrence Local

▪ Treatment options▪ Benefits

Distant▪ Treatment options▪ Benefits

Suggested follow up after treatment

A 48 year old high school teacher presents with progressive dysphagia and weight loss

EGD: large ulcerated nearly circuferential mass in the lower third of

the esophagus. Biopsy: Moderate to poorly differentiated adenocarcinoma

with lymphovascular infiltration.

PET/CT: Intense FDG uptake in paraesophageal lymph nodes. No distant metastases.

EUS: T3 tumor (Nearly circumferential mass, extension into the

adventitia) N1 (multiple enlarged regional lymph nodes)

T3N1 tumor

Treatment: combined modality therapy with radiation and

chemotherapy.

Follow up EGD 75% regression of the mass. Biopsy: residual adenocarcinoma.

Esophagectomy R0 resection Path:

▪ Residual moderately differentiated adenocarcinoma, ▪ foci of carcinoma in 3 regional lymph nodes.

1. Follow up with EGD and CT scan every 3 months

2. Follow up with EGD and CT scan every 6 months

3. Additional radiation therapy to maximal dose

4. Combination salvage chemoXRT

What are the chances of tumor recurrence

What are the usual sites of recurrence Local

▪ Treatment options▪ Benefits

Distant▪ Treatment options▪ Benefits

Suggested follow up after treatment

A 68 year old retired carpenter with a history of CAD, CABG, CHF, COPD, and DM presents with progressive GERD symptoms. No dysphagia or weight loss.

EGD: distal esophagitis with an area of ulceration just proximal

to the GE junction Biopsy: Moderately differentiated adenocarcinoma.

EUS: T2 N0tumor

PET/CT: No abnormal FDG uptake in paraesophageal lymph

nodes. No distant metastases.

Surgical evaluation: Not candidate for resection due to co-morbidities

Treatment: Completes full course of combined chemotherapy and

radiation.

What are the chances of tumor recurrence

What are the usual sites of recurrence: 40% Local

▪ Treatment options: ▪ Benefits

Distant▪ Treatment options▪ Benefits

Suggested follow up after treatment